Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease
largely of complement dysregulation. This advance facilitated the development of novel …

Haemolytic uraemic syndrome (HUS) is a heterogeneous group of diseases that result in a
common pathology, thrombotic microangiopathy, which is classically characterised by the …

Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease
characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) …

Background Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening
disease of chronic uncontrolled complement activation leading to thrombotic …

Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …

Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune
haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the underlying …

We recently observed that dysregulation of the complement system may be involved in the
pathogenesis of hematopoietic stem cell transplantation–associated thrombotic …

Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease
characterized by uncontrolled complement activation, systemic thrombotic microangiopathy …

Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy defined by
thrombocytopenia, nonimmune microangiopathic hemolytic anemia, and acute renal failure …

Ravulizumab, a long-acting complement C5 inhibitor engineered from eculizumab, allows
extending maintenance dosing from every 2–3 weeks to every 4–8 weeks depending on …